Skip to content

    Lung Cancer Health Center

    Font Size
    A
    A
    A

    Chemo Might Give Some Lung Cancer Patients an Edge

    Traditional treatment offers small advantage for people without a specific gene mutation, study says

    WebMD News from HealthDay

    By Randy Dotinga

    HealthDay Reporter

    TUESDAY, April 8, 2014 (HealthDay News) -- Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer.

    Now, a new analysis of existing research finds that traditional chemotherapy outperforms newer, targeted treatments in delaying the time until the cancer worsens for these patients. However, chemo doesn't extend their survival, the review found.

    Patients with non-small cell lung cancer make up 85 percent to 90 percent of lung cancer patients. Some of them have a mutation in a gene that makes their tumors more responsive to medications known as epidermal growth factor receptor tyrosine kinase inhibitors. But most patients with non-small cell lung cancer do not have this mutation, and doctors have been unsure whether this larger group of patients should get chemo or the targeted medication.

    "In our opinion, conventional chemotherapy is a better treatment option for patients if patients are in suitable condition for chemotherapy because it is associated with delayed tumor progression and higher rate of tumor shrinkage," said review co-author Dr. Dong-Wan Kim, of the department of internal medicine at Seoul National University Hospital in South Korea.

    About 10 percent of patients in the West and half of Asian patients have the mutation, according to the study, published in the April 9 issue of the Journal of the American Medical Association.

    People with advanced non-small cell lung cancer typically survive for only 10 to 12 months, said Dr. Suresh Ramalingam, a professor of medical oncology at Emory University's Winship Cancer Institute in Atlanta.

    The authors of the new analysis looked at 11 prior studies that included over 1,600 patients who didn't have the mutation.

    Overall, half of those on traditional chemotherapy lasted 6.4 months or more before their cancer worsened, the study found. But that midpoint, or median, of progression-free survival was just 4.5 months for those who took medications that help lung cancer patients with the mutation -- erlotinib (Tarceva) and gefitinib (Iressa).

    However, the length of time patients lived after the treatment wasn't appreciably different between the two groups.

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
     
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
    Woman getting ct scan
    Article
     
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
    cancer fighting foods
    Article
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO